adMare Industry Builder Series featuring Dr. Jeremy Duffield

Prime Editing, a Next GenerationGene Editing Technology for Therapeutic Uses

On March 13th at 12 pm, Dr. Jeremy Duffield, the Chief Scientific Officer of Prime Medicine, will join adMare's Industry Builder Series to discuss a new gene editing technology, Prime Editing.

Click here to register

Learn more about prime editing

The application of precision gene editing for the correction of disease-associated genetic variants has broad therapeutic potential. Prime Medicine was founded upon a recently developed precision gene editing technology called Prime Editing, a “search-and-replace” editing approach that can precisely perform all 12 single base pair substitutions, sequence-defined insertions and deletions of dozens or more base pairs, and excision of up to thousands of base pairs, all without requiring double-stranded DNA breaks or donor DNA. Because of its versatility, Prime Editing can in principle be used to address a wide range of genetic variants, including small substitutions like the A-to-T transversion that causes sickle cell disease, as well as larger variants like the pathogenic expansions of trinucleotide repeats that cause Huntington’s disease. Building upon seminal work from David Liu’s laboratory, Prime Medicine is expanding the breadth and applicability of Prime Editing through several advancements that improve its efficiency, specificity, and capabilities. Furthermore, by pairing Prime Editing with recombinase enzymes, we are applying Prime Editing for programmable deletion, inversion, and integration of large genetic payloads. In this talk, Dr. Duffield will share data and discuss their progress in advancing our Prime Editing technology for therapeutic applications.

Who is Dr. Jeremy Duffield?

Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine.

Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies.

At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases.

Prior to joining the leadership at Biogen, Dr. Duffield had a distinguished academic career on the faculty at University of Washington and Harvard Medical School as Head of the National Institutes of Health/National Center for Advancing Translational Sciences/American Heart Association-funded Laboratory for Innate Immunity and Regeneration. Dr. Duffield served on NIH study sections, several company scientific advisory boards, is a member of the American Society of Clinical Investigation and received many scientific awards including the ASN-AHA Young Investigator Award and the NIH Early Career Investigator/Scholar Award.